News and trends on diagnostics testing, insurance coverage, and reimbursement.
The agency said its aim is to analyze the way CMS has chosen to implement PAMA and to estimate the potential financial impact to Medicare as a result of those choices.
The diversity of the organizations that have signed the letter to CMS demonstrates widespread concern over this policy.
The non-coverage decision came despite appeals by the company following a draft non-coverage determination issued last year.
After a GAO report found that CMS may be overpaying for lab tests, the legislator is asking the government payor to explain how it will ensure appropriate use of taxpayer funds.
CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.
This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.